BIOLASE, Inc. (NASDAQ:BIOL) Short Interest Up 25.7% in May

BIOLASE, Inc. (NASDAQ:BIOL) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 2,100,000 shares, an increase of 25.7% from the May 15th total of 1,670,000 shares. Based on an average daily trading volume, of 4,790,000 shares, the short-interest ratio is presently 0.4 days. Approximately 6.6% of the shares of the stock are short sold.

BIOLASE Trading Up 3.5 %

Shares of BIOL traded up $0.01 on Monday, reaching $0.15. 1,467,059 shares of the company’s stock were exchanged, compared to its average volume of 3,788,608. The company has a current ratio of 1.17, a quick ratio of 0.64 and a debt-to-equity ratio of 34.06. The stock has a market capitalization of $4.96 million, a P/E ratio of -0.01 and a beta of 0.74. The business has a 50 day moving average price of $0.16 and a two-hundred day moving average price of $0.47. BIOLASE has a 12 month low of $0.13 and a 12 month high of $10.31.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Monday, May 13th. The medical technology company reported ($0.36) EPS for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The firm had revenue of $10.13 million during the quarter.

Analysts Set New Price Targets

A number of research firms have commented on BIOL. Benchmark restated a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research report on Tuesday, May 14th. Maxim Group lowered shares of BIOLASE from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 24th. Finally, StockNews.com started coverage on shares of BIOLASE in a research report on Thursday. They set a “sell” rating on the stock.

Institutional Investors Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Institutional investors own 8.79% of the company’s stock.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.